Beam Therapeutics Insider ownership
What is the Insider ownership of Beam Therapeutics?
The Insider ownership of Beam Therapeutics Inc. is 1.90%
What is the definition of Insider ownership?
Insider Ownership is calculated as the total number of shares owned by insiders (shareholders who own more than 5% of the corporation or an officer or director of the company) divided by the total Shares Outstanding.
A high value of insider ownership means that those working for the company have a large stake in the success of the company. This is sometimes seen as a sign that those running the company will work hard to ensure its success or believe the company's stock price will rise.
A change in insider ownership may come from exercise of option, stock grant and buying or selling of company shares. A purchase of company share signifies a confidence in the company's future performance by people who know the company best. Therefore, Net Insider buying is also an important indicator for investors.
Insider ownership of companies in the Health Care sector on NASDAQ compared to Beam Therapeutics
What does Beam Therapeutics do?
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children's Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration with Apellis Pharmaceuticals, Inc. to apply base editing technology for discovering new treatments for complement-driven diseases. Beam Therapeutics Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Companies with insider ownership similar to Beam Therapeutics
- Five Below Inc has Insider ownership of 1.89%
- Charter Hall Retail Real Estate Investment Trust has Insider ownership of 1.89%
- Coherent Corp has Insider ownership of 1.89%
- Oxford Immunotec Global PLC has Insider ownership of 1.89%
- Silver Lake Resources has Insider ownership of 1.90%
- CryoPort Inc has Insider ownership of 1.90%
- Beam Therapeutics has Insider ownership of 1.90%
- Murata Manufacturing Co has Insider ownership of 1.90%
- Vista Outdoor Inc has Insider ownership of 1.90%
- Timbercreek has Insider ownership of 1.90%
- iRobot has Insider ownership of 1.90%
- Cincinnati has Insider ownership of 1.90%
- AMBAC has Insider ownership of 1.91%